Johnson & Johnson's strategy to outpace its branded pharmaceutical peers by achieving above-market compound annual growth over the five-year period from 2016 to 2021 will require building several blockbuster brands into "mega-blockbusters" and launching new commercial successes, Worldwide Chairman-Pharmaceuticals Joaquin Duato said during an R&D briefing May 17.
The diversified healthcare giant presented a sweeping overview of its pharmaceutical portfolio and pipeline during a five-hour investor meeting
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?